Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some high-level mechanism/description statements align with labeling (e.g., CD38-directed cytolytic antibody; apoptosis/immune effector mechanisms). However, multiple trial/approval/timing and side-effect prevalence statements are not supported by the provided labeling excerpts and some claims exceed the supplied text.
Category Scores
Accurate Statements
Sarclisa (isatuximab-irfc) is a CD38-directed cytolytic antibody that is a monoclonal antibody (IgG1) used in multiple myeloma.
Label excerpt 11 (Description): “Isatuximab-irfc, a CD38-directed cytolytic antibody… chimeric… IgG1… monoclonal antibody.” and 12.1: binds to CD38 on multiple myeloma cells.
Isatuximab-irfc binds to CD38 expressed on the surface of hematopoietic and tumor cells, including multiple myeloma cells.
12.1 Mechanism of Action: “binds to CD38 expressed… including multiple myeloma cells.”
By binding to CD38, isatuximab-irfc induces apoptosis of tumor cells.
12.1: “Isatuximab-irfc induces apoptosis of tumor cells…”
Isatuximab-irfc activates immune effector mechanisms including ADCC, ADCP, and CDC.
12.1: “…activation of immune effector mechanisms including ADCC… ADCP… and CDC.”
Isatuximab-irfc inhibits the ADP-ribosyl cyclase activity of CD38.
12.1: “inhibits the ADP-ribosyl cyclase activity of CD38.”
Unsupported Statements
Sarclisa is a monoclonal antibody used in the treatment of multiple myeloma.
Provided excerpts include mechanism and description but do not explicitly state the indication as a use statement in the snippet for this claim; indication text is present but specific trial/line-of-therapy details are required for full alignment (see indication findings).
CD38 was first identified in the 1980s as a cell surface protein involved in the regulation of calcium levels within cells.
Not supported by the supplied label excerpts (Description/Mechanism/Warnings/Adverse Reactions excerpts provided do not include historical identification or calcium regulation details).
CD38 is overexpressed on the surface of multiple myeloma cells.
Label excerpt states CD38 is expressed on the surface of hematopoietic and tumor cells including multiple myeloma cells, but the claim of “overexpressed” is not explicitly supported in the provided text.
The development of Sarclisa began in the early 2000s when Sanofi and Ono Pharmaceutical formed a partnership to develop an antibody targeting CD38.
Not supported by supplied label excerpts.
Sanofi identified the optimal epitope on CD38 to allow specific binding to multiple myeloma cells.
Not supported by supplied label excerpts.
Sanofi used computational modeling and experimental techniques to optimize Sarclisa's binding affinity and specificity.
Not supported by supplied label excerpts.
Sarclisa preclinical studies tested the antibody in animal models of multiple myeloma to assess how well it works and whether it has toxic effects.
Not supported by supplied label excerpts.
Preclinical studies showed Sarclisa had significant anti-tumor activity in animal models.
Not supported by supplied label excerpts (provided excerpt mentions a human multiple myeloma xenograft model in the mechanism section but does not state “preclinical studies” or “to assess toxic effects” nor “significant anti-tumor activity” in the way asserted).
The ICARIA-MM trial was a Phase 2 study enrolling patients with relapsed or refractory multiple myeloma.
The supplied excerpts mention ICARIA-MM only within warnings (as a clinical trial name) but do not provide phase, enrollment criteria, or patient population details.
Results of the ICARIA-MM trial showed Sarclisa significantly improved progression-free survival compared to the control arm.
Not supported by supplied excerpts (no clinical study efficacy results text provided).
Results of the ICARIA-MM trial showed Sarclisa significantly improved overall response rate compared to the control arm.
Not supported by supplied excerpts (no clinical study efficacy results text provided).
The US FDA approved Sarclisa in 2019 for the treatment of relapsed or refractory multiple myeloma.
Not supported by supplied excerpts (no approval date or approval-history text provided).
Sarclisa is currently being investigated in several ongoing clinical trials.
Not supported by supplied excerpts.
A Phase 3 trial is investigating Sarclisa in combination with carfilzomib and dexamethasone in patients with multiple myeloma.
Not supported by supplied excerpts (no Phase 3 trial description provided).
The most common side effects of Sarclisa include infusion-related reactions, fatigue, and diarrhea.
Supplied excerpts provide infusion-related reactions details but do not provide a “most common side effects” list including fatigue and diarrhea, and no adverse reaction frequency table/list is included in the provided text.
Sarclisa is currently approved in several countries, including the US, EU, and Japan.
Not supported by supplied excerpts.
Contradictions
Low
AI Statement
Sarclisa preclinical studies tested the antibody in animal models of multiple myeloma to assess how well it works and whether it has toxic effects.
Label Reference
No direct contradiction in supplied text; instead, the claim is unsupported. Marked as contradiction only if label explicitly denies animal tox assessment, which is not present.
Important Omissions
No dosing/administration regimen (including premedication and infusion monitoring instructions) was evaluated against the label, despite multiple safety-related statements being made without citing label-based administration steps.
Importance:
Moderate
When discussing clinical evidence (e.g., ICARIA-MM), label-adherent statements about trial outcomes require the provided section with clinical study results; none were included in the supplied excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Mechanism and binding are supported, but multiple safety-related claims (e.g., “most common side effects” including fatigue/diarrhea) and trial/approval assertions are not supported by the provided labeling excerpts; additionally, omission of label-specific infusion reaction management details could lead to incomplete understanding of risks described in Warnings and Precautions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Many claims (trial phase/results, FDA approval year, development history, and common side effects beyond infusion-related reactions) are not supported by the provided label excerpts.
Suggested Improvement
Limit statements to what is explicitly present in the supplied label text (e.g., CD38 binding; apoptosis/ADCC/ADCP/CDC; infusion-related reactions incidence and management steps). For efficacy/approval timing, use label sections that contain clinical study results and regulatory history not included in the provided excerpts.